Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P JAFFE

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Alimentary Pharmacology & Therapeutics|July 25, 2000
Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacidsD Earnest, M Robinson, S Rodriguez-Stanley, et al.
Archives of Internal Medicine|November 25, 1998
Heartburn requiring frequent antacid use may indicate significant illnessM Robinson, D Earnest, S Rodriguez-Stanley, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Alimentary Pharmacology & Therapeutics|July 25, 2000
Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacidsD Earnest, M Robinson, S Rodriguez-Stanley, et al.
Archives of Internal Medicine|November 25, 1998
Heartburn requiring frequent antacid use may indicate significant illnessM Robinson, D Earnest, S Rodriguez-Stanley, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
Pageof 4